Searchable abstracts of presentations at key conferences in endocrinology

ea010248 | Diabetes, Obesity and Metabolism | EYES2024

There is a need for better implementation of DKA guidelines - findings from the DEKODE DKA study

Chackalaparambil Philip Nevil , Ann Abraham Anu , Rengarajan Lakshmi , Kempegowda Punith

Introduction: In 2021, a new recommendation was put forward by the Joint British Diabetes Society-Inpatient (JBDS-IP) group to reduce fixed rate intravenous insulin infusion (FRIII) from 0.1 to 0.05 units/kg/hour when blood glucose falls <14 mmol/l in the management of Diabetic Ketoacidosis (DKA). This helped reduce the risk of associated complications. However, there has not been any evidence on whether this has been appropriately implemented. Metho...

ea0104p84 | Diabetes & Metabolism | SFEIES24

Implementation of diabetic ketoacidosis guidelines and its impact on patient outcomes

Abraham Anu , Duggal Manbir , Govindaraj Sureshkumar Ragavendran , Kempegowda Punith

Introduction: Revised guidelines by the Joint British Diabetes Society-Inpatient (JBDS-IP) recommend reducing the fixed rate intravenous insulin infusion (FRIII) from 0.1 to 0.05 units/kg/hour and starting 10% glucose at 125 ml/hour when blood glucose levels fall below 14 mmol/l.Aim: This study evaluates trends in implementation, associated outcomes with the revised JBDS-IP guidelines for DKA management in the UK.Methods: A retrosp...

ea0094p215 | Metabolism, Obesity and Diabetes | SFEBES2023

Trends in the rate of complications and outcomes in DKA management following modifications in JBDS national guidelines-Results from DEKODE study

Abraham Anu , Solomon Alexandra , Birchenough Amy , Cheung Jason , Rengarajan Lakshmi , Hebbar Meghna , Ali Karamat Muhammad , Ahmed Nabeel , De Parijat , Soghal Shamanth , Working group DEKODE , Falowo Durodoluwa

Introduction: Joint British Diabetes Societies Inpatient (JBDS-IP) recommended reducing fixed-rate intravenous insulin infusion (FRIII) rate to 0.05units/kg/hr when blood glucose falls <14 mmol/l to avoid hypoglycaemia during diabetes-related ketoacidosis (DKA).Aim: We studied the impact of guideline change on complications and outcomes of DKA.Methods: We included all DKA episo...

ea0099oc12.4 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Characteristics and outcomes of DKA in people taking SGLT2 inhibitors: DEKODE study

Mathur Nitish , Sharma Angelica , Philip Nevil , Rengarajan Lakshmi , Bomphrey Lucy , Abraham Anu , Saraf Sanjay , Dhatariya Ketan , Kempegowda Punith , Working Group Dekode

Background: Although SGLT2 inhibitors (SGLT2-i) have revolutionised the management of diabetes, they are associated with an increased risk of developing diabetic ketoacidosis (DKA). However, there remains a paucity of evidence about the risk factors, management, and outcomes of DKA episodes associated with SGLT2-i therapy. Improved understanding of these factors in order to optimise education, minimise risk, and improve outcomes of DKA episodes in individuals receiving SGLT2-i...